OTC Markets OTCPK - Delayed Quote USD

Ligand Pharmaceuticals Incorporated (LGNDZ)

0.0023

-0.0007

(-23.33%)

At close: April 23 at 2:30:03 PM EDT

Ligand to Report First Quarter 2025 Financial Results on May 8, 2025

JUPITER, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report first quarter 2025 financial results before the opening of the U.S. financial markets on Thursday, May 8, 2025. The company will hold a conference call that same day beginning at 8:30 a.m. ET to discuss the results and provide a general business update. Conference Call and Webcast InformationDate: Thursday, May 8, 2025 Time: 8:30 AM Eastern Time Conference Call

GlobeNewswire 12 hours ago

LGND

LGNDZ
-23.33%
LGNXZ
+18.18%
LGND: Pelthos To Become Public Company

By John Vandermosten, CFA NASDAQ:LGND READ THE FULL LGND RESEARCH REPORT Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) announced that it had identified a suitor to take its subsidiary Pelthos Therapeutics public in an April 17 th press release . Ligand’s subsidiary will combine with the public company Channel Therapeutics (NYSE: CHRO) which is a clinical stage life sciences company developing

Zacks Small Cap Research yesterday

LGNZZ
-7.69%
CHRO
Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics

Proposed transaction will raise $50 million in equity capital and enhance a publicly traded biopharmaceutical company focused on launching Pelthos’ ZELSUVMI™ ZELSUVMI is an FDA-designated novel drug and the first and only prescription medication approved for the treatment of Molluscum contagiosum infections administered at home by parents, patients, and caregivers Ligand is entitled to a 13% royalty on worldwide sales of ZELSUVMI Transaction is expected to close in the summer of 2025 JUPITER, Fl

GlobeNewswire 7 days ago

LGND

LGNDZ
-23.33%
LGNXZ
+18.18%
EXCLUSIVE: Ligand Subsidiary Pelthos Therapeutics To Combine with Channel Therapeutics Creating Pain Medicines Focused Entity

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) and Channel Therapeutics Corporation (NYSE:CHRO) on Thursday signed a definitive merger agreement to combine Ligand’s wholly owned subsidiaries, Pelthos Therapeutics Inc. and LNHC, Inc. (collectively Pelthos) with CHRO Merger Sub Inc., a wholly owned subsidiary of Channel. The merger will be supported by $50 million in capital raised from a group of strategic investors led by Murchinson. Under the merger agreement, Channel will acquire 100% of Pe

Benzinga 7 days ago

CHRO

LGNZZ
-7.69%
Top March 2025 Stocks Estimated To Be Trading Below Their Intrinsic Value

As the U.S. stock market faces a turbulent period with major indices like the Dow Jones and S&P 500 on track for their worst week in two years, concerns about tariffs and economic health continue to dominate investor sentiment. In such uncertain times, identifying stocks that are trading below their intrinsic value can offer potential opportunities for investors looking to navigate these challenging conditions.

Simply Wall St. last month

LGND

LGNDZ
-23.33%
LGNXZ
+18.18%
Ligand to Participate in March Investor Conferences

JUPITER, Fla., March 03, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in the following upcoming investor conferences: Leerink Partners Global Healthcare Conference (Miami). Management will participate in one-on-one meetings on March 10, 2025. Barclays 27th Annual Global Healthcare Conference (Miami). Management will participate in a fireside chat on Ma

GlobeNewswire last month

LGND

LGNDZ
-23.33%
LGNXZ
+18.18%
LGND: First Steps into Cell & Gene Therapy

By John Vandermosten, CFA NASDAQ:LGND READ THE FULL LGND RESEARCH REPORT Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) reported 2024 financial and operational results posting revenues of $167 million, a 27% rise over prior year levels. Drivers for the result were a 30% increase in royalty revenues and a 44% increase in contract revenue. Adjusted core earnings per share were $5.74, up from 2023’s

Zacks Small Cap Research last month

LGNZZ
-7.69%
Ligand Pharmaceuticals Inc (LGND) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...

Despite a GAAP net loss, Ligand Pharmaceuticals Inc (LGND) showcases robust financial health and promising new ventures in its latest earnings call.

GuruFocus.com last month

LGNZZ
-7.69%
Ligand: Q4 Earnings Snapshot

JUPITER, Fla. AP) — Ligand Pharmaceuticals Inc. LGND) on Thursday reported a loss of $31.1 million in its fourth quarter.

Associated Press Finance last month

LGNZZ
-7.69%
Ligand Reports Fourth Quarter and Full Year 2024 Financial Results

Robust financial performance driven by full year 2024 royalty revenue growth of 28% Reiterating 2025 financial guidance of $180-$200 million in revenues and adjusted earnings per diluted share1 of $6.00-$6.25 Conference call and webcast at 8:30 a.m. Eastern time today JUPITER, Fla., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and twelve months ended December 31, 2024, and provided an operating forecast and bu

GlobeNewswire last month

LGND

LGNDZ
-23.33%
LGNXZ
+18.18%
Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences

Capital will fund Castle Creek’s D-Fi Phase 3 clinical trial for patients with dystrophic epidermolysis bullosa through topline data results Ligand invested $50 million and a syndicate of co-investors invested $25 million in return for a high-single digit royalty on D-Fi JUPITER, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has closed a royalty financing agreement with Castle Creek Biosciences, Inc. to support the Phase 3 clinical

GlobeNewswire last month

LGND

LGNDZ
-23.33%
LGNXZ
+18.18%
Ligand to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

JUPITER, Fla., February 13, 2025--Ligand to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

Business Wire 2 months ago

LGND

LGNDZ
-23.33%
LGNXZ
+18.18%
Ligand to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

JUPITER, Fla., February 06, 2025--Ligand to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Business Wire 2 months ago

LGND

LGNDZ
-23.33%
LGNXZ
+18.18%
Zacks Small Cap Research 2024 Initiations and Best Ideas for 2025

Zacks Small Cap Research was hard at work in 2024 initiating analyst coverage on 40 companies. Each of our initiation reports provides a valuation, investment thesis and financial forecast model that comes from our 11 experienced analysts’ expertise and due diligence. Our work has generated investment ideas in health care, consumer electronics, finance technologies, transportation, AI-based

Zacks Small Cap Research 3 months ago

MTVA

LGNZZ
-7.69%
TELO
Ligand Pharmaceuticals (NASDAQ:LGND) shareholders have earned a 59% return over the last year

Passive investing in index funds can generate returns that roughly match the overall market. But investors can boost...

Simply Wall St. 3 months ago

LGND

LGNDZ
-23.33%
LGNXZ
+18.18%
LGND: 2025 View Calls for 17% Topline Growth

By John Vandermosten, CFA NASDAQ:LGND READ THE FULL LGND RESEARCH REPORT Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) held its annual analyst day on December 10 th , 2024 in Boston. The company provided its 2025 expectations calling for topline revenues of $180 to $200 million and core adjusted earnings per share (EPS) of $6.00 to $6.25. This represents an approximate 17% increase at the midpoint

Zacks Small Cap Research 4 months ago

LGNZZ
-7.69%
Ligand price target raised to $151 from $135 at Oppenheimer

Oppenheimer raised the firm’s price target on Ligand (LGND) to $151 from $135 and keeps an Outperform rating on the shares following the company’s investor day. Key takeaways, the firm says, include capital needs within biotech/biopharma remain massive; investments will continue to be selective, and lean on their expertise; Zelsuvmi opportunity remains underappreciated; further levers of potential value creation exist with an emphasis on Captisol sales growth; and Captisol/Nitricil platform valu

TipRanks 4 months ago

LGND

LGNDZ
-23.33%
LGNXZ
+18.18%
Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance

JUPITER, Fla., December 10, 2024--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) will host its Investor and Analyst Day in Boston today. The event will feature presentations from Ligand CEO Todd Davis, CFO Tavo Espinoza, and other members of the senior management team who will provide an in-depth review of the company’s growth strategy, portfolio, platform technologies, and long-term financial outlook.

Business Wire 4 months ago

LGND

LGNDZ
-23.33%
LGNXZ
+18.18%
Ligand Pharmaceuticals (NASDAQ:LGND) Shareholders Should Be Cautious Despite Solid Earnings

Shareholders were pleased with the recent earnings report from Ligand Pharmaceuticals Incorporated ( NASDAQ:LGND...

Simply Wall St. 5 months ago

LGND

LGNDZ
-23.33%
LGNXZ
+18.18%
Ligand to Present at Stifel 2024 Healthcare Conference

JUPITER, Fla., November 14, 2024--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will present at the Stifel 2024 Healthcare Conference in New York on Tuesday, November 19, 2024, at 12:40 p.m. Eastern Time.

Business Wire 5 months ago

LGND

LGNDZ
-23.33%
LGNXZ
+18.18%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Ligand Pharmaceuticals Incorporated (LGNDZ)

Ligand to Report First Quarter 2025 Financial Results on May 8, 2025

LGND: Pelthos To Become Public Company

Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics

EXCLUSIVE: Ligand Subsidiary Pelthos Therapeutics To Combine with Channel Therapeutics Creating Pain Medicines Focused Entity

Top March 2025 Stocks Estimated To Be Trading Below Their Intrinsic Value

Ligand to Participate in March Investor Conferences

LGND: First Steps into Cell & Gene Therapy

Ligand Pharmaceuticals Inc (LGND) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...

Ligand: Q4 Earnings Snapshot

Ligand Reports Fourth Quarter and Full Year 2024 Financial Results

Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences

Ligand to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

Ligand to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Zacks Small Cap Research 2024 Initiations and Best Ideas for 2025

Ligand Pharmaceuticals (NASDAQ:LGND) shareholders have earned a 59% return over the last year

LGND: 2025 View Calls for 17% Topline Growth

Ligand price target raised to $151 from $135 at Oppenheimer

Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance

Ligand Pharmaceuticals (NASDAQ:LGND) Shareholders Should Be Cautious Despite Solid Earnings

Ligand to Present at Stifel 2024 Healthcare Conference